Albumin replacement in patients with severe sepsis or septic shock

Pietro Caironi, Gianni Tognoni, Serge Masson, Roberto Fumagalli, Antonio Pesenti, Marilena Romero, Caterina Fanizza, Luisa Caspani, Stefano Faenza, Giacomo Grasselli, Gaetano Iapichino, Massimo Antonelli, Vieri Parrini, Gilberto Fiore, Roberto Latini, Luciano Gattinoni

Research output: Contribution to journalArticle

430 Citations (Scopus)

Abstract

BACKGROUND: Although previous studies have suggested the potential advantages of albumin administration in patients with severe sepsis, its efficacy has not been fully established. METHODS: In this multicenter, open-label trial, we randomly assigned 1818 patients with severe sepsis, in 100 intensive care units (ICUs), to receive either 20% albumin and crystalloid solution or crystalloid solution alone. In the albumin group, the target serum albumin concentration was 30 g per liter or more until discharge from the ICU or 28 days after randomization. The primary outcome was death from any cause at 28 days. Secondary outcomes were death from any cause at 90 days, the number of patients with organ dysfunction and the degree of dysfunction, and length of stay in the ICU and the hospital. RESULTS: During the first 7 days, patients in the albumin group, as compared with those in the crystalloid group, had a higher mean arterial pressure (P = 0.03) and lower net fluid balance (P

Original languageEnglish
Pages (from-to)1412-1421
Number of pages10
JournalNew England Journal of Medicine
Volume370
Issue number15
DOIs
Publication statusPublished - 2014

Fingerprint

Septic Shock
Albumins
Sepsis
Intensive Care Units
Cause of Death
Water-Electrolyte Balance
Random Allocation
Serum Albumin
Length of Stay
Arterial Pressure
crystalloid solutions

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Caironi, P., Tognoni, G., Masson, S., Fumagalli, R., Pesenti, A., Romero, M., ... Gattinoni, L. (2014). Albumin replacement in patients with severe sepsis or septic shock. New England Journal of Medicine, 370(15), 1412-1421. https://doi.org/10.1056/NEJMoa1305727

Albumin replacement in patients with severe sepsis or septic shock. / Caironi, Pietro; Tognoni, Gianni; Masson, Serge; Fumagalli, Roberto; Pesenti, Antonio; Romero, Marilena; Fanizza, Caterina; Caspani, Luisa; Faenza, Stefano; Grasselli, Giacomo; Iapichino, Gaetano; Antonelli, Massimo; Parrini, Vieri; Fiore, Gilberto; Latini, Roberto; Gattinoni, Luciano.

In: New England Journal of Medicine, Vol. 370, No. 15, 2014, p. 1412-1421.

Research output: Contribution to journalArticle

Caironi, P, Tognoni, G, Masson, S, Fumagalli, R, Pesenti, A, Romero, M, Fanizza, C, Caspani, L, Faenza, S, Grasselli, G, Iapichino, G, Antonelli, M, Parrini, V, Fiore, G, Latini, R & Gattinoni, L 2014, 'Albumin replacement in patients with severe sepsis or septic shock', New England Journal of Medicine, vol. 370, no. 15, pp. 1412-1421. https://doi.org/10.1056/NEJMoa1305727
Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M et al. Albumin replacement in patients with severe sepsis or septic shock. New England Journal of Medicine. 2014;370(15):1412-1421. https://doi.org/10.1056/NEJMoa1305727
Caironi, Pietro ; Tognoni, Gianni ; Masson, Serge ; Fumagalli, Roberto ; Pesenti, Antonio ; Romero, Marilena ; Fanizza, Caterina ; Caspani, Luisa ; Faenza, Stefano ; Grasselli, Giacomo ; Iapichino, Gaetano ; Antonelli, Massimo ; Parrini, Vieri ; Fiore, Gilberto ; Latini, Roberto ; Gattinoni, Luciano. / Albumin replacement in patients with severe sepsis or septic shock. In: New England Journal of Medicine. 2014 ; Vol. 370, No. 15. pp. 1412-1421.
@article{f55bf467c2fd494bba5ec881c38b6d10,
title = "Albumin replacement in patients with severe sepsis or septic shock",
abstract = "BACKGROUND: Although previous studies have suggested the potential advantages of albumin administration in patients with severe sepsis, its efficacy has not been fully established. METHODS: In this multicenter, open-label trial, we randomly assigned 1818 patients with severe sepsis, in 100 intensive care units (ICUs), to receive either 20{\%} albumin and crystalloid solution or crystalloid solution alone. In the albumin group, the target serum albumin concentration was 30 g per liter or more until discharge from the ICU or 28 days after randomization. The primary outcome was death from any cause at 28 days. Secondary outcomes were death from any cause at 90 days, the number of patients with organ dysfunction and the degree of dysfunction, and length of stay in the ICU and the hospital. RESULTS: During the first 7 days, patients in the albumin group, as compared with those in the crystalloid group, had a higher mean arterial pressure (P = 0.03) and lower net fluid balance (P",
author = "Pietro Caironi and Gianni Tognoni and Serge Masson and Roberto Fumagalli and Antonio Pesenti and Marilena Romero and Caterina Fanizza and Luisa Caspani and Stefano Faenza and Giacomo Grasselli and Gaetano Iapichino and Massimo Antonelli and Vieri Parrini and Gilberto Fiore and Roberto Latini and Luciano Gattinoni",
year = "2014",
doi = "10.1056/NEJMoa1305727",
language = "English",
volume = "370",
pages = "1412--1421",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "15",

}

TY - JOUR

T1 - Albumin replacement in patients with severe sepsis or septic shock

AU - Caironi, Pietro

AU - Tognoni, Gianni

AU - Masson, Serge

AU - Fumagalli, Roberto

AU - Pesenti, Antonio

AU - Romero, Marilena

AU - Fanizza, Caterina

AU - Caspani, Luisa

AU - Faenza, Stefano

AU - Grasselli, Giacomo

AU - Iapichino, Gaetano

AU - Antonelli, Massimo

AU - Parrini, Vieri

AU - Fiore, Gilberto

AU - Latini, Roberto

AU - Gattinoni, Luciano

PY - 2014

Y1 - 2014

N2 - BACKGROUND: Although previous studies have suggested the potential advantages of albumin administration in patients with severe sepsis, its efficacy has not been fully established. METHODS: In this multicenter, open-label trial, we randomly assigned 1818 patients with severe sepsis, in 100 intensive care units (ICUs), to receive either 20% albumin and crystalloid solution or crystalloid solution alone. In the albumin group, the target serum albumin concentration was 30 g per liter or more until discharge from the ICU or 28 days after randomization. The primary outcome was death from any cause at 28 days. Secondary outcomes were death from any cause at 90 days, the number of patients with organ dysfunction and the degree of dysfunction, and length of stay in the ICU and the hospital. RESULTS: During the first 7 days, patients in the albumin group, as compared with those in the crystalloid group, had a higher mean arterial pressure (P = 0.03) and lower net fluid balance (P

AB - BACKGROUND: Although previous studies have suggested the potential advantages of albumin administration in patients with severe sepsis, its efficacy has not been fully established. METHODS: In this multicenter, open-label trial, we randomly assigned 1818 patients with severe sepsis, in 100 intensive care units (ICUs), to receive either 20% albumin and crystalloid solution or crystalloid solution alone. In the albumin group, the target serum albumin concentration was 30 g per liter or more until discharge from the ICU or 28 days after randomization. The primary outcome was death from any cause at 28 days. Secondary outcomes were death from any cause at 90 days, the number of patients with organ dysfunction and the degree of dysfunction, and length of stay in the ICU and the hospital. RESULTS: During the first 7 days, patients in the albumin group, as compared with those in the crystalloid group, had a higher mean arterial pressure (P = 0.03) and lower net fluid balance (P

UR - http://www.scopus.com/inward/record.url?scp=84898487262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898487262&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1305727

DO - 10.1056/NEJMoa1305727

M3 - Article

C2 - 24635772

AN - SCOPUS:84898487262

VL - 370

SP - 1412

EP - 1421

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 15

ER -